

RealRate

PHARMACEUTICAL 2021











RealRate



XBiotech Inc. Rank 4 of 402

The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of XBiotech Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 328%, being 281% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	325,875
Cost of Goods Sold	34,548
Intangible Assets	0
Liabilities, Current	3,984
Liabilities, Non-Current	0
Other Assets	533
Other Compr. Net Income	1,372
Other Expenses	-1,606
Other Liabilities	1,121
Other Net Income	5,449
Other Revenues	43,997
Property and Equipment	27,336
Research and Development	9,527
Selling, General and Administrative Expense	18,198

Output Variable	Value in 1000 USD
Assets	353,744
Liabilities	5,105
Expenses	60,667
Revenues	43,997
Stockholders Equity	348,639
Net Income	-11,221
Comprehensive Net Income	-10,535
Economic Capital Ratio	328%

